Author Contributions

Secondary Analyses

Design of secondary analyses: L.V. Wain, G.B. Ehret, M.J. Caulfield, H. Snieder, M.D. Tobin, R. Joehanes, A. Vaez, R. Jansen, A.V. Smith, J. Knight, P.F. O'Reilly, A.P. Morris, and C.P. Cabrera. Computation of secondary analysis: L.V. Wain, G.B. Ehret, A.P. Morris, A.M. Erzurumluoglu, T. Blake, L. Lin, R. Joehanes, A. Vaez, P.J. van der Most, R. Jansen, and C.P. Cabrera.

Discovery

WGHS: Study phenotyping, P.M. Ridker; Genotyping or analysis, D.I. Chasman and L.M. Rose; Study PI, D.I. Chasman and P.M. Ridker.

RS: Study phenotyping, G.C. Verwoert; Genotyping or analysis, G.C. Verwoert and A.G. Uitterlinden; Study PI, O.H. Franco, A. Hofman, and A.G. Uitterlinden.

NTR: Study phenotyping, E.J. de Geus and G. Willemsen; Genotyping or analysis: J.-J. Hottenga, E.J. de Geus, and G. Willemsen; Study PI, D.I. Boomsma and E.J. de Geus.

STR: Study phenotyping, E. Ingelsson; Genotyping or analysis, R.J. Strawbridge and M. Frånberg; Study PI, E. Ingelsson and A. Hamsten.

EGCUT: Genotyping or analysis, T. Esko; Study PI, A. Metspalu.

ARIC: Genotyping or analysis, D.E. Arking, A.C. Morrison, and P. Nandakumar; Study PI, A. Chakravarti.

FHS: Study phenotyping, D. Levy; Genotyping or analysis, S.-J. Hwang; Study PI: D. Levy.

MESA: Study phenotyping, J.I. Rotter; Genotyping or analysis, W. Palmas, X. Guo, J.I. Rotter, J. Yao; Study PI, W. Palmas.

B58C: Study phenotyping, D.P. Strachan; Genotyping or analysis, D.P. Strachan; Study PI, D.P. Strachan.

COLAUS: Study phenotyping, P. Vollenweider; Genotyping or analysis, M. Bochud and Z. Kutalik; Study PI, P. Vollenweider.

PROSPER: Study phenotyping, J.W. Jukema and D.J. Stott; Genotyping or analysis, S. Trompet and J. Deelen; Study PI, J.W. Jukema.

BHS: Study phenotyping, A. James; Genotyping or analysis, N. Shrine, J. Hui, and J. Beilby.

SHIP: Study phenotyping, M. Dörr; Genotyping or analysis, A. Teumer, M. Dörr, and U. Völker; Study PI, R. Rettig.

KORA S4: Genotyping or analysis, J.S. Ried; Study PI, A. Peters.

CHS: Study phenotyping, B.M. Psaty; Genotyping or analysis, J.C. Bis, K. Rice, and K.D. Taylor; Study PI, B.M. Psaty.

AGES-Reykjavik: Genotyping or analysis, A.V. Smith; Study PI, V. Gudnason, T.B. Harris, and L.J. Launer.

ERF: Study phenotyping, C.M. van Duijn and B.A. Oostra; Genotyping or analysis, N. Amin; Study PI, C.M. van Duijn and B.A. Oostra.

NESDA: Study phenotyping, B.W.J.H. Penninx; Genotyping or analysis, I.M. Nolte and Y. Milaneschi; Study PI, H. Snieder and B.W.J.H. Penninx.

YFS: Study phenotyping, T. Lehtimäki, M. Kähönen, and O.T. Raitakari; Genotyping or analysis, T. Lehtimäki, L.-P. Lyytikäinen, M. Kähönen, and O.T. Raitakari; Study PI, T. Lehtimäki, M. Kähönen, and O.T. Raitakari.

EPIC: Genotyping or analysis, N.J. Wareham; Study PI, J.H. Zhao.

ASPS: Study phenotyping, R. Schmidt; Genotyping or analysis, H. Schmidt, E. Hofer, Y. Saba, and R. Schmidt; Study PI, H. Schmidt and R. Schmidt.

ORCADES: Study phenotyping, J.F. Wilson, H. Campbell, and S. Wild; Genotyping or analysis, J.F. Wilson, P.K. Joshi, and S. Wild; Study PI, J.F. Wilson.

FINRISK (COROGENE_CTRL): Study phenotyping, P. Jousilahti; Genotyping or analysis, K. Kristiansson and A.P. Sarin; Study PI, M. Perola and P. Jousilahti.

INGI-VB: Study phenotyping, C.F. Sala; Genotyping or analysis, M. Traglia, C.M. Barbieri, and C.F. Sala; Study PI, D. Toniolo.

FINRISK_PREDICT_CVD: Study phenotyping, V. Salomaa and A.S. Havulinna; Study PI, V. Salomaa, A. Palotie, and S. Ripatti.

TRAILS: Study phenotyping, H. Riese; Genotyping or analysis, P.J. van der Most; Study PI, C.A. Hartman and A.J. Oldehinkel.

PROCARDIS: Study phenotyping, A. Goel; Genotyping or analysis, A. Goel; Study PI, H. Watkins, and M. Farrall.

HABC: Study phenotyping, Y. Liu and T.B. Harris; Genotyping or analysis, M.A. Nalls; Study PI, Y. Liu and T.B. Harris.

KORA S3: Study phenotyping, C. Gieger; Genotyping or analysis, S. Sõber, C. Gieger, and E. Org. Study PI, M. Laan.

INGI-FVG: Genotyping or analysis, D. Vuckovic, M. Brumat, and M. Cocca; Study PI, P. Gasparini.

Fenland: Study phenotyping, R.A. Scott, J. Luan, C. Langenberg, and N.J. Wareham; Genotyping or analysis, R.A. Scott, J. Luan, C. Langenberg, and N.J. Wareham; Study PI, R.A. Scott, C. Langenberg, and N.J. Wareham.

MICROS: Genotyping or analysis, A.A. Hicks, F. Del Greco M., and A. Saint Pierre; Study PI, F. Del Greco M. and P.P. Pramstaller.

HTO: Study phenotyping, B.D. Keavney; Genotyping or analysis, B.D. Keavney, K.L. Ayers, and C. Mamasoula; Study PI, B.D. Keavney and H.J. Cordell.

MIGEN: Study phenotyping, R. Elosua, J. Marrugat, S. Kathiresan, and D. Siscovick; Genotyping or analysis, R. Elosua, S. Kathiresan, and D. Siscovick; Study PI, S. Kathiresan.

Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets

ULSAM: Study phenotyping, V. Giedraitis and E. Ingelsson; Genotyping or analysis, A.P. Morris and A. Mahajan; Study PI, A.P. Morris, V. Giedraitis, and E. Ingelsson.

Cilento study: Study phenotyping, R. Sorice; Genotyping or analysis, D. Ruggiero, and T. Nutile; Study PI, M. Ciullo.

LBC1936: Study phenotyping, I.J. Deary and A.J. Gow; Genotyping or analysis, L.M. Lopez, G. Davies, and A.J. Gow; Study PI, I.J. Deary.

H2000_CTRL: Study phenotyping, T. Niiranen; Study PI, P. Knekt, A. Jula, and S. Koskinen.

NSPHS: Genotyping or analysis, S. Enroth and Å. Johansson; Study PI, U. Gyllensten.

FUSION: Genotyping or analysis, A.U. Jackson; Study PI, J. Tuomilehto, M. Boehnke, and F. Collins.

GRAPHIC: Study phenotyping, N.J. Samani, P.S. Braund, and M.D. Tobin. Genotyping or analysis: C.P. Nelson, P.S. Braund, and M.D. Tobin; Study PI, N.J. Samani.

CROATIA_Vis: Study phenotyping, I. Rudan; Genotyping or analysis, V. Vitart and J.E. Huffman; Study PI, V. Vitart and I. Rudan.

PIVUS: Study phenotyping, L. Lind and J. Sundström; Genotyping or analysis, C.M. Lindgren and A. Mahajan; Study PI, C.M. Lindgren, L. Lind, and J. Sundström.

LOLIPOP: Study phenotyping, J.S. Kooner and J.C. Chambers; Genotyping or analysis, J.S. Kooner, W. Zhang, J.C. Chambers, and B. Lehne; Study PI, J.S. Kooner and J.C. Chambers.

CROATIA_Korcula: Genotyping or analysis, C. Hayward and J. Marten; Study PI, C. Hayward and A.F. Wright.

INGI-CARL: Study phenotyping, G. Girotto; Genotyping or analysis, I. Gandin, A. Morgan, and A. Robino.

LBC1921: Study phenotyping, J.M. Starr and A. Pattie; Genotyping or analysis, J.M. Starr, S.E. Harris, D.C.M. Liewald, and A. Pattie; Study PI, J.M. Starr.

CROATIA_SPLIT: Study phenotyping, O. Polasek and I. Kolcic; Genotyping or analysis, O. Polasek and T. Zemunik; Study PI, O. Polasek.

BioMe (formerly IPM): Genotyping or analysis, Y. Lu; Study PI, R.J.F. Loos and E.P. Bottinger.

Replication

UKB-BP: Genotyping or analysis, H.R. Warren, M.R. Barnes, C.P. Cabrera, E. Evangelou, H. Gao, B. Mifsud, M. Ren, and I. Tzoulaki; Study PI, P. Elliott and M.J. Caulfield.

GoDARTS: Study phenotyping, C.N.A. Palmer and A.S.F. Doney; Genotyping or analysis, C.N.A. Palmer and N. Shah; Study PI, C.N.A. Palmer and A.D. Morris.

Lifelines: Study phenotyping: M.H. de Borst; Genotyping or analysis, M. Swertz; Study PI, P. van der Harst.

TwinsUK: Study phenotyping, C. Menni; Genotyping or analysis, M. Mangino and C. Menni; Study PI, T.D. Spector.

Airwave Health Monitoring Study: Genotyping or analysis, A.C. Vergnaud, E. Evangelou, H. Gao, and I. Tzoulaki; Study PI, E. Evangelou.

The UK Household Longitudinal Study (UKHLS): Genotyping or analysis, B.P. Prins; Study PI, E. Zeggini.

Generation Scotland (GS:SFHS): Study phenotyping, S. Padmanabhan; Genotyping or analysis, C. Hayward and A. Campbell.

JUPITER: Study phenotyping, P.M. Ridker; Genotyping or analysis, D.I. Chasman, L.M. Rose, F. Giulianini, and P.M. Ridker; Study PI, D.I. Chasman and P.M. Ridker.

NEO: Study phenotyping, R. de Mutsert; Genotyping or analysis, D.O. Mook-Kanamori and R. Li-Gao; Study PI, R. de Mutsert.

Three City-Dijon: Study phenotyping, S. Debette and C. Tzourio; Genotyping or analysis, G. Chauhan; Study PI, S. Debette and C. Tzourio.

ASCOT-UK: Study phenotyping: P. Sever and N. Poulter; Genotyping or analysis, P.B. Munroe and H.R. Warren; Study PI, P.B. Munroe, P. Sever, N. Poulter, and M.J. Caulfield.

ASCOT-SC: Study phenotyping, S. Thom and M.J. Caulfield; Genotyping or analysis, D.C. Shields, A. Stanton, H.R. Warren, and P.B. Munroe; Study PI, S. Thom, M.J. Caulfield, and P.B. Munroe.

Hunter Community Study: Study phenotyping, R. Scott; Genotyping or analysis, C. Oldmeadow and E.G. Holliday; Study PI, J. Attia.

GAPP: Study phenotyping, D. Conen; Genotyping or analysis, D. Conen, S. Thériault, and G. Paré; Study PI, D. Conen.

BRIGHT: Study phenotyping, M. Brown and J. Connell; Genotyping or analysis, M. Farrall, P.B. Munroe, and H.R. Warren; Study PI, M. Brown, J. Connell, M. Farrall, P.B. Munroe, and M.J. Caulfield.

Resources for Secondary Analyses

eQTL NESDA NTR: Design of secondary analysis, R. Jansen; Computation of secondary analysis, D.I. Boomsma, R. Jansen, and B.W.J.H. Penninx; Study PI, D.I. Boomsma and B.W.J.H. Penninx.

eQTL kidney: Study phenotyping, J.J. Damman and M.A. Seelen; Genotyping or analysis, P.J. van der Most; Study PI, H. Snieder.

eQTL BIOS: Design of secondary analysis, R. Jansen; Computation of secondary analysis, R. Jansen; Study PI, R. Jansen.

SABRe: Study phenotyping, Y. Demirkale, P.J. Munson, and Q.T. Nguyen; Genotyping or analysis, R. Joehanes; Design of secondary analysis, D. Levy; Study PI, D. Levy.

ICBP-Steering Committee

G. Abecasis, M.J. Caulfield, A. Chakravarti, D.I. Chasman, G.B. Ehret, P. Elliott, T. Ferreira, M.-R. Jarvelin, A.D. Johnson, M. Larson, D. Levy, A.P. Morris, P.B. Munroe, C. Newton-Cheh, P.F. O'Reilly, W. Palmas, B.M. Psaty, K. Rice, A.V. Smith, H. Snieder, M.D. Tobin, C.M. van Duijn, L.V. Wain, H.R. Warren.

From Blood and the Kidney

A full list of authors and affiliations appears at the end of the article.

Abstract

Elevated blood pressure is a major risk factor for cardiovascular disease and has a substantial genetic contribution. Genetic variation influencing blood pressure has the potential to identify new pharmacological targets for the treatment of hypertension. To discover additional novel blood pressure loci, we used 1000 Genomes Project–based imputation in 150 134 European ancestry individuals and sought significant evidence for independent replication in a further 228 245 individuals. We report 6 new signals of association in or near *HSPB7, TNXB, LRP12, LOC283335, SEPT9*, and *AKT2*, and provide new replication evidence for a further 2 signals in *EBF2* and *NFKBIA*. Combining large whole-blood gene expression resources totaling 12 607 individuals, we investigated all novel and previously reported signals and identified 48 genes with evidence for involvement in blood pressure regulation that are significant in multiple resources. Three novel kidney-specific signals were also detected. These robustly implicated genes may provide new leads for therapeutic innovation.

Keywords

Genetic support for a drug target increases the likelihood of success in drug development,[1] and there is clear unmet need for novel therapeutic strategies to treat individuals with hypertension.[2] Several large studies have described blood pressure (BP) variant identification by genome-wide and targeted association approaches.[3–19] Clinically, the most predictive BP traits for cardiovascular risk are systolic BP (SBP) and diastolic BP (DBP), reflecting roughly the peak and trough of the BP curve, and pulse pressure, the difference between SBP and DBP,[20] reflecting arterial stiffness. Using these 3 traits, we undertook a meta-analysis of 150 134 individuals from 54 genome-wide association studies (GWAS) of European ancestry with imputation based on the 1000 Genomes Project Phase 1. To minimize reporting of false-positive associations, we sought stringent evidence for significant independent replication in a further 228 245 individuals. We further followed up novel and previously reported association signals in multiple large gene expression databases and the largest kidney tissue gene expression resource currently available. Finally, we searched for enrichment of associated genes in biological pathways and gene sets and identified whether any of the genes were known drug targets or had tool molecules.

Materials and Methods

Studies Stage 1

Results from 54 independent European-ancestry studies, totaling 150 134 individuals, were included in the stage 1 meta-analysis: AGES (n=3215), ARIC (n=9402), ASPS (n=828), B58C (n=6458), BHS (n=4492), CHS (n=3254), Cilento study (n=999), COLAUS

(n=5404), COROGENE-CTRL (n=1878), CROATIA-Vis (n=945), CROATIA-Split (n=494), CROATIA-Korcula (n=867), EGCUT (n=6395), EGCUT2 (n=1844), EPIC (n=2100), ERF (n=2617), Fenland (n=1357), FHS (n=8096), FINRISK-ctrl (n=861), FINRISK CASE (n=839), FUSION (n=1045), GRAPHIC (n=1010), H2000-CTRL (n=1078), HealthABC (n=1661), HTO (n=1000), INGI-CARL (n=456), INGI-FVG (n=746), INGI-VB (n=1775), IPM (n=300), KORAS3 (n=1590), KORAS4 (n=3748), LBC1921 (n=376), LBC1936 (n=800), LOLIPOP-EW610 (n=927), MESA (n=2678), MICROS (n=1148), MIGEN (n=1214), NESDA (n=2336), NSPHS (n=1005), NTR (n=1490), PHASE (n=4535), PIVUS (n=945), PROCARDIS (n=1652), SHIP (n=4068), ULSAM (n=1114), WGHS (n=23 049), YFS (n=1987), ORCADES (n=1908), RS1 (n=5645), RS2 (n=2152), RS3 (n=3018), TRAILS (n=1262), TRAILS-CC (n=282), and TWINGENE (n=9789). Full study names and general study information is given in Table S1 in the online-only Data Supplement.

Study-Level Genotyping and Association Testing

Three quantitative BP traits were analyzed: SBP, DBP, and pulse pressure (difference between SBP and DBP). Within each study, individuals known to be taking antihypertensive medication had 15 mm Hg added to their raw SBP value and 10 mm Hg added to their raw DBP values.[21] A summary of BP phenotypes in each study is given in Table S2. Association testing was undertaken according to a central analysis plan that specified the use of sex, age, age^2, and body mass index as covariates and optional inclusion of additional covariates to account for population stratification (Table S3). Trait residuals were calculated for each trait using a normal linear regression of the medication-adjusted trait values (mm Hg) onto all covariates. The genotyping array, preimputation quality control filters, imputation software, and association testing software used by each study are listed in Table S4. Each participating study imputed genotypes based on the 1000 Genomes Project Phase 1 integrated release version 3 (March 2012) all ancestry reference panel.[22] Imputed genotype dosages were used to take into account uncertainty in the imputation. Association testing was performed using linear regression of the trait residuals onto genotype dosages under an additive genetic model. Methods to account for relatedness within a study were used where appropriate (Table S3). Results for all variants (single nucleotide polymorphisms [SNPs] and insertion/deletion polymorphisms [INDELs]) were then returned to the central analysis group for further quality control checks and meta-analysis.

Stage 1 Meta-Analysis

Central quality control checks were undertaken across all results sets. This included checks to ensure allele frequency consistency (across studies and with reference populations), checks of effect size and standard error distributions (ie, to highlight phenotype issues), and generation of quantile–quantile plots and genomic inflation factor lambdas to check for over- or underinflation of test statistics. Genomic control was applied (if lambda >1) at study level. Variants with imputation quality <0.3 were excluded prior to meta-analysis. Inverse variance–weighted meta-analysis was undertaken. After meta-analysis, variants with a weighted minor allele frequency of <1% or N effective (product of study sample size and imputation quality summed across contributing studies) <60% were then excluded and meta-analysis genomic control lambda calculated and used to adjust the meta-analysis results.

Selection of Regions for Follow-Up

For each trait, regions of association were selected by ranking variants by P value, recording the variant with the lowest P value as a sentinel variant and then excluding all variants ±500 kb from the sentinel and reranking the remaining variants. This was undertaken iteratively until all sentinel variants representing 1 Mb regions containing associations with $P<10^{-6}$ had been identified. To identify additional signals represented by secondary sentinel variants within 500 kb of each of the sentinel variants, GCTA (the Genome-wide Complex Trait Analysis software)[23] was used to run conditional analyses (conditioned on the first sentinel variant) on each of the 1 Mb regions using GWAS summary statistics and linkage disequilibrium (LD) information from ARIC. This was done both for putatively novel regions and for regions that had previously been reported. A χ^2 test of heterogeneity of effect sizes across the 54 studies was run for each sentinel variant, and those with $P<0.05$ for heterogeneity were excluded from further follow-up. Variants with $P<10^{-6}$ after conditioning on the sentinel SNP (novel or known) in the region and for which any attenuation of the −log10 P value was <1.5 fold were also taken forward for replication.

Studies Stage 2

Data from 14 independent studies, totaling 87 360 individuals, and the first release of UK Biobank, totaling 140 886 individuals, were combined to replicate the findings from stage 1 (ie, totaling 228 245 individuals). Stage 2 study details, including full study names, are given in Table S6 and included 3C-Dijon (n=4061), Airwave (n=14 023), ASCOT-SC (n=2462), ASCOT-UK (n=3803), BRIGHT (n=1791), GAPP (n=1685), GoDARTs (n=7413), GS:SFHS (n=9749), HCS (n=2112), JUPITER (n=8718), LifeLines (n=13 376), NEO (n=5731), TwinsUK (n=4973), UK Biobank-CMC (n=140 886), and UKHLS (n=7462). Analysis was undertaken using the same methods as described for stage 1 studies. UK Biobank-CMC used a newer imputation reference panel than the other studies, and where a requested variant was not available, a proxy was used (next most significant P value with LD r^2>0.6 with original top variant). Results from all stage 2 studies were meta-analyzed using inverse variance–weighted meta-analysis. Two of the variants, rs1048238 and chr1:243458005:INDEL, were not available in the largest study in stage 2 (UK Biobank-CMC), and so proxy variants were selected (based on P value and LD).

Stage 1+Stage 2 Meta-Analysis

After meta-analysis of stage 1 and stage 2 results, signals with a $P>5\times10^{-8}$ were excluded. Of the signals with a final $P<5\times10^{-8}$, support for independent replication within the stage 2 studies only was sought. Any signals that had $P<5\times10^{-8}$ and evidence for independent replication in stage 2 alone indicated by $P<8.2\times10^{-4}$ (Bonferroni correction for 61 tests) were reported as novel signals of association with BP. Any signals that were subsequently reported by other BP GWAS that were accepted for publication during the time this analysis was ongoing, or signals for which independence from another known signal could not be established, were removed from our list of novel signals at this stage (Table S5).

Genotype and Gene Expression

We searched for signals of association of genotype with gene expression for the 22 signals (including 8 novel) described in this study (Table S7) and all signals reported prior to our study (Table S10)[3–16,18,24] in 3 whole-blood data sets, 1 kidney data set, and the GTEx (Genotype-Tissue Expression) multiple tissue data resource, which included whole blood.[25] We selected cis signals of association, which were significant after controlling for 5% false discovery rate. The 3 whole-blood expression quantitative trait loci (eQTL) data sets were the National Heart, Lung, and Blood Institute SABRe (Systems Approach to Biomarker Research in Cardiovascular Disease) initiative whole-blood eQTL resource (microarray, n=5257), NESDA-NTR (microarray, n=4896), BIOS (RNAseq, n=2116). The whole-blood data from GTEx was based on data from 338 samples. The kidney data set comprised 236 donor kidney samples from 134 donors.[26] Full details of each data set can be found in the online-only Data Supplement. The source transcriptomic renal data as described[26] have been deposited in the GeneExpression Omnibus (NCBI) and are accessible online through GEO Series accession number GSE43974.

LD Lookup

The 1000 Genomes Project phase 3 release of variant calls was used (February 20, 2015) using 503 subjects of European ancestry.[22] r^2 between the sentinel SNPs and all other biallelic SNPs within the corresponding 2 Mb area were calculated using the Tabix and PLINK software package (v1.07).[27,28] Annotation was performed using the ANNOVAR software package.[29]

Gene-Based Pathway Analysis

All genes identified in 3 or 4 of the whole-blood eQTL resources above (Table 2) and genes containing a nonsynonymous variant with r^2>0.5 with the sentinel variant (Table S14) were tested for enrichment of biological pathways and gene ontology (GO) terms using ConsensusPathDB[30] using a false discovery rate <5% cutoff. Enriched pathways and GO terms containing genes only implicated by a single BP-associated variant were not reported.

Network Analysis

To construct a functional association network, we combined 2 prioritized candidate gene sets into a single query gene set as (1) genes mapping to the nonsynonymous SNPs in high LD (r^2>0.5) with the corresponding sentinel BP-associated SNP and (2) genes with eQTL evidence from 3 or 4 of the blood eQTL resources. Three sentinel SNPs (rs185819, rs926552, and rs805303) mapping to the HLA (human leukocyte antigen) region on chromosome 6 were excluded from downstream analyses. The single query gene set was then used as input for the functional network analysis.[31] We used the Cytoscape[32] software platform extended by the GeneMANIA[33] plugin (Data Version: August 12, 2014).[34] All the genes in the composite network, either from the query or the resulting gene sets, were then used for functional enrichment analysis against GO terms[35] to identify the most relevant GO terms using the same plugin.[34]

DNase1 Hypersensitivity Overlap Enrichment Across Tissue and Cell Types

The functional element overlap analysis of the results of GWAS experiments (Forge tool v1.1)[36] was used to test for enrichment of overlap of BP SNPs in tissues and cell lines from the Roadmap and ENCODE (Encyclopedia of DNA Elements) projects. All 164 SNPs were entered and 143 were included in the analysis. SNPs from 9 commonly used GWAS arrays were used to select background sets of SNPs for comparison, and 10 000 background repetitions were run. A Z score threshold of 3.39 (estimated false-positive rate of 0.5%) was used to declare significance.

Drug–Gene Interactions

Genes used for pathway and GO enrichment analyses were further investigated for potential druggable or drugged targets using DGIdb (drug gene interaction database).[37] Known drug–gene interactions were interrogated across 15 source databases in DGIdb and include all types of interactions. The analysis performed for druggability prediction included all 9 databases exclusively inspecting expert curated data only. We also evaluate genes for known tool compounds using Chembl (www.ebi.ac.uk/chembl/; version 22.1).

Results

The stage 1 discovery meta-analysis included 150 134 individuals (Tables S1 through S4 and Figures S1 and S2) and 7 994 604 variants with minor allele frequency >1% and an effective sample size of at least 60% of the total. We used the widely used 2-stage design[38] and identified 61 signals in the discovery analysis that were candidates for novel BP signals ($P<10^{-6}$ for any trait; Table S5). To ensure robustness of signals, we examined BP associations in an additional 228 245 individuals from 15 independent studies for replication, including 140 886 individuals from UK Biobank[19] (Table S6). We used the most significant (sentinel) SNP and trait for each locus in replication (61 tests). Twenty-two putatively novel association signals were initially confirmed, showing significant evidence of replication in the independent stage-2 studies ($P<8.2\times10^{-4}$, Bonferroni correction for 61 tests) and genome-wide significance ($P<5\times10^{-8}$) in a meta-analysis across all 378 376 individuals (Table 1 and Table S7). Of these, 14 were subsequently published in 2 other studies[17,19] which presented genome-wide significant associations with evidence of replication. A further 2 were highlighted as putative novel signals in one of those studies[17] but had not been confirmed by replication. In our study, we report the 6 remaining novel signals, and the 2 previously unconfirmed signals (in *EBF2* and in *NFKBIA*), as novel signals. The 8 novel signals included 7 signals at 7 independent loci (Figure S3) and 1 novel independent signal near a previously reported hit near *TNXB* (Table S8 and Figure S4). The novel signals show both significant evidence of replication in the independent stage-2 studies ($P<8.2\times10^{-4}$, Bonferroni correction for 61 tests) and genome-wide significance ($P<5\times10^{-8}$) in a meta-analysis across all 378 376 individuals. The sentinel variants at all 8 signals were common (minor allele frequency >5%), and the novel secondary signal at *TNXB* was in high linkage disequilibrium ($r^2>0.8$) with a nonsynonymous SNP. With the exception of rs9710247, which was only significant for association with DBP, all signals were significantly associated ($P<0.006$, Bonferroni corrected for 8 tests) with all 3 traits (Table 1 and Table S9).

We next sought to identify which genes might have expression levels that were associated with genotypes of the BP-associated variants reported in this study and others. Strong evidence of an association with expression of a specific gene may provide clues as to which gene(s) might be functionally relevant to that signal. We took the 139 BP association signals reported prior to these studies[17,19] and 22 novel signals of association identified and confirmed in this study and 2 contemporaneous studies[3–19,24] (Table S10) and searched for evidence of association with gene expression in whole blood (4 studies, total n=12 607; supporting information in the online-only Data Supplement) and in kidney tissue (n=134, the largest kidney eQTL resource currently available). Although of unclear direct relevance to BP, whole blood was studied because of the availability of large data sets enabling a powerful assessment of expression patterns that are likely present across multiple cell and tissue types. Similarly, circulating blood cells have been used for ion transport experiments in the past, and altered ion transport levels in erythrocytes were linked to hypertension.[39] Kidney was chosen because of the many renal pathways that regulate BP and outstanding questions about the relevance of kidney pathways to the genetic component of BP regulation in the general population.[3,15] eQTL signals were filtered by false discovery rate (<5%), and we examined *cis* (within 1 Mb) associations only (supporting information in the online-only Data Supplement).

The 4 blood eQTL data sets were NESDA-NTR,[40,41] SABRe,[15] the BIOS resource,[42] and GTEx[25] (supporting information in the online-only Data Supplement). The BIOS resource (n=2116) has not previously been used in the analysis of BP associations, and findings from NESDA-NTR and SABRe have been reported for a subset of the previously published signals.[16,18] For a total of 369 genes, gene expression was associated with the BP SNP in 1 of the 4 blood data sets at experiment-wide significance (Table S11). This included 14 genes for 6 of the 8 novel signals. For 110 genes, we found eQTL evidence in 2 out of 4 data sets (Figure), including 4 genes for 2 of the novel signals: *EIF4B* and *TNS2* for rs73099903 and *MAP3K10* and *PLD3* for rs9710247. SNP rs73099903 was in strong LD ($r^2 > 0.9$), with the SNP most strongly associated with *TNS2* expression in the BIOS resource. *TNS2* encodes a tensin focal adhesion molecule and may have a role in renal function.[43]

For 48 genes, we found evidence in 3 out of the 4 resources (Table 2), suggesting robustness of the SNP–gene expression correlation signal and highlighting those genes as potential candidates in genetic BP regulation. Of the 48 genes, 28 have not previously been described in eQTL analyses using BP-associated SNPs, and all were correlated with previously reported BP association signals.

In the kidney data set (TransplantLines),[26] there was association of gene expression and genotype for 9 SNPs and 13 genes (Table 2 and Figure; Table S12). Nine of the SNP–gene expression associations were also observed in the whole-blood eQTL data sets, suggesting that those signals may not be unique to the kidney. We report 3 signals that were unique to the kidney and not previously reported (*C4orf34, HIP2*, and *ASIC1*) and confirm a previously reported kidney eQTL signal for an antisense RNA for *PSMD5*.[15] The same SNP was also an eQTL for *PSMD5* itself in both blood and kidney. *ASIC1* encodes the acid sensing ion channel subunit 1, which may interact (and be coexpressed) with ENaC subunits, which mediate transepithelial Na transport in the distal nephron of the kidney.[44] The

comparatively small number of signals using kidney tissue (Table 2 and Figure) compared with whole blood could be because of the small sample size. Complete GTEx results are given in Table S13.

For genes implicated by eQTL information from whole blood, we tested for enrichment of biological pathways and GOs. We noted enrichment of the 48 genes implicated by 3 or 4 blood eQTL resources (Table 2) and a further 54 genes containing a nonsynonymous variant with $r^2 > 0.5$ with the top SNP (Table S14) in pathways and ontology terms related to actin and striated muscle (Tables S15 and S16). Network analysis using the same genes highlighted further GO terms relating to muscle function, particularly cardiac muscle (Table S17). We tested the overlap of 161 non-HLA BP-associated variants with DNase hypersensitivity sites identified in the Roadmap and ENCODE cell lines and identified an overall enrichment in multiple cell and tissue types, including heart, kidney, and smooth muscle (Figure S5).

We next investigated these genes for potential suitability as drug targets (druggability), known tool compounds, and clinically approved drugs using DGIdb[37] (Table S18). Twelve genes had known drugs, including 4 genes with known antihypertensive drugs. We noted that drugs modulating all but 1 of the 12 drugged targets had a reported influence on BP, either as a primary antihypertensive indication or as a reported side effect of raised BP. Twenty additional genes were predicted druggable, among these 7 genes have known small molecule tool modulators, based on a query of the Chembl database (www.ebi.ac.uk/chembldb/; version 22.1).

Discussion

Enhanced discovery of BP loci increases the potential targets for therapeutic advances. After major advances in the number of BP loci known over the last years and months, we report 8 novel signals that implicate 5 regions of the genome not previously connected to BP regulation.

Six of the 8 novel signals we report had not previously been reported. Two signals (in *EBF2* and *NFKBIA*) have been suggested previously but without evidence for replication.[17] For these 2 signals, we present, for the first time, stringent evidence of replication, confirming their relevance to BP genetics.

The path from signal to genes is the essential next step toward realizing the therapeutic potential of a genetic locus and understanding the mechanisms of BP regulation. We have used several large eQTL resources as a first step to realize this objective. As expected, we observed that even across eQTL studies of the same tissue, there is limited overlap in experiment-wide significant signals, suggesting either biological variability (differences in the characteristics of the samples or in the methods for extraction and processing of mRNA in each of the studies), technology-specific differences in coverage of genes (use of RNAseq data for the BIOS blood data set and microarray-based expression levels for the kidney and other blood data sets), or the possibility of false-positive results despite stringent within-experiment significance thresholds. We were unable to distinguish these scenarios

using the data available to us, but by selecting genes that were significant in at least 3 resources, and therefore robust to these differences, we identified 48 genes as candidates for further study. These results are limited by the availability of large eQTL resources for whole blood only, which precludes well-powered comparisons across tissue types, particularly, as the origin of BP control is unlikely to be located in the blood. Enrichment and pathway analyses using these genes, and genes containing a correlated functional variant, highlight the potential relevance of muscular tissue and pathways, compatible with a vascular and cardiac origin of BP genetics, extending previous evidence.[15] We identify several drugged targets in the pathways identified, including 4 existing hypertension targets. Other drugs identified are not suitable candidates for repositioning to hypertension because most were reported in adverse events to raise BP; however, the targets would be valid for investigation using a reverse mechanism, for example, agonism in place of inhibition. We also identified 7 genes with small molecule tool modulators (mainly inhibitory or binding). These molecules and targets might be suitable candidates for further investigation to build a target validation case to support clinical investigation in hypertension.

Among the genes implicated in our eQTL, analyses were several for which there is already some evidence that they are relevant to BP regulation. The intronic SNP rs10926988 was independently associated with expression of *SDCCAG8* in all 4 whole-blood resources. Rare mutations in *SDCCAG8* cause Bardet–Biedl syndrome, which features hypertension. Expression levels of *MYBPC3* were correlated with rs7103648[15] in the 3 largest blood eQTL resources (ie, SABRe, NESDA-NTR, and BIOS). *MYBPC3* encodes the cardiac isoform of myosin-binding protein C, which is expressed in heart muscle, and mutations in *MYBPC3* are known to cause familial hypertrophic cardiomyopathy.[45]

This study has several limitations. Given the nature of statistical power for genome-wide association analyses, the sample size is limited, even though this is one of the largest efforts in BP GWAS undertaken to date. The study would clearly have benefited from the availability of larger eQTL resources on multiple tissues in sample sizes even larger than those available today. Our analyses were limited to *cis* signals, and future analyses, with larger sample sizes, might also consider *trans* signals.

Perspectives

Our study reports robust novel BP association signals and reports new candidate BP genes, contributing to the transition from variants to genes to explain BP variation. These genes now require further functional validation to establish their potential as drug targets. Our study additionally highlights the challenges of combining and interpreting data from multiple eQTL studies and emphasizes the need for harmonization of data and development of new eQTL resources for multiple tissue types.

In summary, our study reports novel BP association signals and reports new candidate BP genes, contributing to the transition from variants to genes to explain BP variation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Louise V. Wain,

Ahmad Vaez,

Rick Jansen,

Roby Joehanes,

Peter J. van der Most,

A. Mesut Erzurumluoglu,

Paul F. O'Reilly,

Claudia P. Cabrera,

Helen R. Warren,

Lynda M. Rose,

Germaine C. Verwoert,

Jouke-Jan Hottenga,

Rona J. Strawbridge,

Tonu Esko,

Dan E. Arking,

Shih-Jen Hwang,

Xiuqing Guo,

Zoltan Kutalik,

Stella Trompet,

Nick Shrine,

Alexander Teumer,

Janina S. Ried,

Joshua C. Bis,

Albert V. Smith,

Najaf Amin,

Ilja M. Nolte,

Leo-Pekka Lyytikäinen,

Anubha Mahajan,

Nicholas J. Wareham,

Edith Hofer,

Peter K. Joshi,

Kati Kristiansson,

Michela Traglia,

Aki S. Havulinna,

Anuj Goel,

Mike A. Nalls,

Siim Sõber,

Dragana Vuckovic,

Jian'an Luan,

M. Fabiola Del Greco,

Kristin L. Ayers,

Jaume Marrugat,

Daniela Ruggiero,

Lorna M. Lopez,

Teemu Niiranen,

Stefan Enroth,

Anne U. Jackson,

Christopher P. Nelson,

Jennifer E. Huffman,

Weihua Zhang,

Jonathan Marten,

Ilaria Gandin,

Sarah E. Harris,

Tatijana Zemunik,

Yingchang Lu,

Evangelos Evangelou,

Nabi Shah,

Martin H. de Borst,

Massimo Mangino,

Bram P. Prins,

Archie Campbell,

Ruifang Li-Gao,

Ganesh Chauhan,

Christopher Oldmeadow,

Gonçalo Abecasis,

Maryam Abedi,

Caterina M. Barbieri,

Michael R. Barnes,

Chiara Batini,

John Beilby,

BIOS Consortium[*],

Tineka Blake,

Michael Boehnke,

Erwin P. Bottinger,

Peter S. Braund,

Morris Brown,

Marco Brumat,

Harry Campbell,

John C. Chambers,

Massimiliano Cocca,

Francis Collins,

John Connell,

Heather J. Cordell,

Jeffrey J. Damman,

Gail Davies,

Eco J. de Geus,

Renée de Mutsert,

Joris Deelen,

Yusuf Demirkale,

Alex S.F. Doney,

Marcus Dörr,

Martin Farrall,

Teresa Ferreira,

Mattias Frånberg,

He Gao,

Vilmantas Giedraitis,

Christian Gieger,

Franco Giulianini,

Alan J. Gow,

Anders Hamsten,

Tamara B. Harris,

Albert Hofman,

Elizabeth G. Holliday,

Jennie Hui,

Marjo-Riitta Jarvelin,

Åsa Johansson,

Andrew D. Johnson,

Pekka Jousilahti,

Antti Jula,

Mika Kähönen,

Sekar Kathiresan,

Kay-Tee Khaw,

Ivana Kolcic,

Seppo Koskinen,

Claudia Langenberg,

Marty Larson,

Lenore J. Launer,

Benjamin Lehne,

David C.M. Liewald,

Lifelines Cohort Study[*],

Li Lin,

Lars Lind,

François Mach,

Chrysovalanto Mamasoula,

Cristina Menni,

Borbala Mifsud,

Yuri Milaneschi,

Anna Morgan,

Andrew D. Morris,

Alanna C. Morrison,

Peter J. Munson,

Priyanka Nandakumar,

Quang Tri Nguyen,

Teresa Nutile,

Albertine J. Oldehinkel,

Ben A. Oostra,

Elin Org,

Sandosh Padmanabhan,

Aarno Palotie,

Guillaume Paré,

Alison Pattie,

Brenda W.J.H. Penninx,

Neil Poulter,

Peter P. Pramstaller,

Olli T. Raitakari,

Meixia Ren,

Kenneth Rice,

Paul M. Ridker,

Harriëtte Riese,

Samuli Ripatti,

Antonietta Robino,

Jerome I. Rotter,

Igor Rudan,

Yasaman Saba,

Aude Saint Pierre,

Cinzia F. Sala,

Antti-Pekka Sarin,

Reinhold Schmidt,

Rodney Scott,

Marc A. Seelen,

Denis C. Shields,

David Siscovick,

Rossella Sorice,

Alice Stanton,

David J. Stott,

Johan Sundström,

Morris Swertz,

Kent D. Taylor,

Simon Thom,

Ioanna Tzoulaki,

Christophe Tzourio,

André G. Uitterlinden,

Understanding Society Scientific Group[*],

Uwe Völker,

Peter Vollenweider,

Sarah Wild,

Gonneke Willemsen,

Alan F. Wright,

Jie Yao,

Sébastien Thériault,

David Conen,

John Attia,

Peter Sever,

Stéphanie Debette,

Dennis O. Mook-Kanamori,

Eleftheria Zeggini,

Tim D. Spector,

Pim van der Harst,

Colin N.A. Palmer,

Anne-Claire Vergnaud,

Ruth J.F. Loos,

Ozren Polasek,

John M. Starr,

Giorgia Girotto,

Caroline Hayward,

Jaspal S. Kooner,

Cecila M. Lindgren,

Veronique Vitart,

Nilesh J. Samani,

Jaakko Tuomilehto,

Ulf Gyllensten,

Paul Knekt,

Ian J. Deary,

Marina Ciullo,

Roberto Elosua,

Bernard D. Keavney,

Andrew A. Hicks,

Robert A. Scott,

Paolo Gasparini,

Maris Laan,

YongMei Liu,

Hugh Watkins,

Catharina A. Hartman,

Veikko Salomaa,

Daniela Toniolo,

Markus Perola,

James F. Wilson,

Helena Schmidt,

Jing Hua Zhao,

Terho Lehtimäki,

Cornelia M. van Duijn,

Vilmundur Gudnason,

Bruce M. Psaty,

Annette Peters,

Rainer Rettig,

Alan James,

J. Wouter Jukema,

David P. Strachan,

Walter Palmas,

Andres Metspalu,

Erik Ingelsson,

Dorret I. Boomsma,

Oscar H. Franco,

Murielle Bochud,

Christopher Newton-Cheh,

Patricia B. Munroe,

Paul Elliott,

Daniel I. Chasman,

Aravinda Chakravarti,

Joanne Knight,

Andrew P. Morris,

Daniel Levy,

Martin D. Tobin,

Harold Snieder[†],

Mark J. Caulfield[†],

Georg B. Ehret[†]

Affiliations

Department of Health Sciences (L.V.W., A.M.E., N. Shrine, C.B., T.B., M.D.T.), and Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre (C.P.N., P.S.B., N.J.S.), University of Leicester, United Kingdom; Department of Epidemiology (A.V., P.J.v.d.M., I.M.N., H. Snieder), Division of Nephrology, Department of Internal Medicine (M.H.d.B., M.A.S.), Interdisciplinary Center Psychopathology and Emotion Regulation (IPCE) (A.J.O., H.R., C.A.H.), Department of Genetics, (M.S.), and Department of Cardiology (P.v.d.H.), University of Groningen, University Medical Center Groningen, The Netherlands; Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Iran (A.V.); Department of Psychiatry, VU University Medical Center, Neuroscience Campus Amsterdam, The Netherlands (R. Jansen); Hebrew SeniorLife, Harvard Medical School, Boston, MA (R. Joehanes); National Heart, Lung and Blood Institute's Framingham Heart Study, MA (R. Joehanes, A.D.J., M. Larson); Institute of Psychiatry, Psychology and Neuroscience (P.F.O.), and Department of Twin Research and Genetic Epidemiology (M.M., C. Menni, T.D.S.), King's College London, United Kingdom; Clinical Pharmacology, William Harvey Research Institute (C.P.C., H.R.W., M.R.B., M. Brown, B.M., M.R., P.B.M., M.J.C.) and NIHR Barts Cardiovascular Biomedical Research Unit (C.P.C., H.R.W., M.R.B., M. Brown, P.B.M., M.J.C.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA (L.M.R., F.G., P.M.R., D.I.C.); Department of Epidemiology (G.C.V., A. Hofman, A.G.U., O.H.F.), Genetic Epidemiology Unit, Department of Epidemiology (N.A., B.A.O., C.M.v.D.), and Department of Internal Medicine (A.G.U.), Erasmus MC, Rotterdam, The Netherlands; Department of Biological Psychology, Vrije Universiteit, Amsterdam, EMGO+ Institute, VU University Medical Center, The Netherlands (J.-J.H., E.J.d.G., G.W., D.I.B.); Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (R.J.S., M. Frånberg, A. Hamsten); Centre

for Molecular Medicine, Karolinska Universitetsjukhuset, Solna, Sweden (R.J.S., M. Frånberg, A. Hamsten); Estonian Genome Center (T.E., E.O., A. Metspalu), Institute of Biomedicine and Translational Medicine (S.S., M. Laan), and Estonian Genome Center (M.P.), University of Tartu, Estonia; Divisions of Endocrinology/ Children's Hospital, Boston, MA (T.E.); Broad Institute of Harvard and MIT, Cambridge, MA (T.E., C.M.L., C.N.-C.); Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (D.E.A., P.N., A. Chakravarti, G.B.E.); The Population Science Branch, Division of Intramural Research, National Heart Lung and Blood Institute (S.-J.H., D.L.), Laboratory of Neurogenetics, National Institute on Aging (M.A.N.), Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute (F.C.), and Center for Information Technology (Y.D., P.J.M., Q.T.N.), National Institutes of Health, Bethesda, MD; The Framingham Heart Study, Framingham, MA (S.-J.H., D.L.); The Institute for Translational Genomics and Population Sciences, Department of Pediatrics (X.G., J.Y.), and The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine (J.I.R.), LABioMed at Harbor-UCLA Medical Center, Torrance, CA; Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland (Z.K., M. Bochud); Swiss Institute of Bioinformatics, Lausanne, Switzerland (Z.K.); Department of Cardiology (S. Trompet, J.W.J.) Department of Gerontology and Geriatrics (S. Trompet), Department of Clinical Epidemiology (R.L.-G., R.d.M., D.O.M.-K.), Department of Molecular Epidemiology (J.D.), and Department of Public Health and Primary Care (D.O.M.-K.), Leiden University Medical Center, The Netherlands; Institute for Community Medicine (A.T.), Department of Internal Medicine B (M.D.), and Interfaculty Institute for Genetics and Functional Genomics (U.V.), University Medicine Greifswald, Germany; DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Germany (A.T., M.D., U.V.); Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany (J.S.R., A. Peters); Cardiovascular Health Research Unit, Department of Medicine (J.C.B., B.M.P.) and Departments of Biostatistics (K.R.), Epidemiology (B.M.P.), and Health Services (B.M.P.), University of Washington, Seattle; Icelandic Heart Association, Kopavogur, Iceland (A.V.S., V. Gudnason); Faculty of Medicine, University of Iceland, Reykjavik, Iceland (A.V.S., V. Gudnason); Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland (L.-P.L., T.L.); Department of Clinical Chemistry, Faculty of Medicine and Life Sciences, University of Tampere, Finland (L.-P.L., T.L.); Wellcome Trust Centre for Human Genetics (A. Mahajan, A.G., M. Farrall, T.F., C.M.L., H.W., A.P.M.), and Division of Cardiovascular Medicine, Radcliffe Department of Medicine (A.G., M. Farrall, H.W.), University of Oxford, United Kingdom; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, United Kingdom (N.J.W., J.L., C.L., R.J.F.L., R.A.S., J.H.Z.); Clinical Division of Neurogeriatrics, Department of Neurology (E.H., R. Schmidt), Institute of Medical Informatics, Statistics and Documentation (E.H.), and Department of Neurology (H. Schmidt), Medical University Graz, Austria; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics (P.K.J., H.C., I.R.,

S.W., J.F.W.), Centre for Cognitive Ageing and Cognitive Epidemiology (L.M.L., S.E.H., G.D., A.J.G., D.C.M.L., J.M.S., I.J.D.), Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine (A. Campbell), Generation Scotland, Centre for Genomic and Experimental Medicine (A. Campbell, S.P., C.H.), Department of Psychology (G.D., D.C.M.L., A. Pattie, I.J.D.), Alzheimer Scotland Dementia Research Centre (J.M.S.), and Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine (C.H.), University of Edinburgh, Scotland, United Kingdom; Department of Health (K.K., A.S.H., T. Niiranen, P.J., A.J., S. Koskinen, P.K., V.S., M.P.), and Chronic Disease Prevention Unit (J.T.), National Institute for Health and Welfare (THL), Helsinki, Finland; Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy (M.T., C.M.B., C.F.S., D.T.); Data Tecnica International, Glen Echo, MD (M.A.N.); Medical Genetics, IRCCS-Burlo Garofolo Children Hospital, Trieste, Italy (D.V., G.G., P.G.); Department of Medical, Surgical and Health Sciences, University of Trieste, Italy (D.V., I.G., M. Brumat, M. Cocca, A. Morgan, G.G., P.G.); Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy (F.D.G.M., P.P.P., A.S.P., A.A.H.); Department of Genetics and Genomic Sciences (K.L.A.), The Charles Bronfman Institute for Personalized Medicine (Y.L., E.P.B., R.J.F.L.), and Mindich Child health Development Institute (R.J.F.L.), Icahn School of Medicine at Mount Sinai, New York; Cardiovascular Epidemiology and Genetics, IMIM, and CIBERCV, Barcelona, Spain (J. Marrugat, R.E.); Institute of Genetics and Biophysics A. Buzzati-Traverso, CNR, Napoli, Italy (D.R., T. Nutile, R. Sorice, M. Ciullo); Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin (L.M.L.); UCD Conway Institute, Centre for Proteome Research (L.M.L.), and School of Medicine, Conway Institute (D.C.S.), University College Dublin, Belfield, Ireland; Department of Immunology, Genetics and Pathology, Uppsala Universitet, Science for Life Laboratory, Sweden (S.E., Å. Johansson, U.G.); Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor (A.U.J., M. Boehnke); NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester United Kingdom (C.P.N., P.S.B., N.J.S.); MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine (J.E.H., V.V., J. Marten, A.F.W., J.F.W.), and Medical Genetics Section, Centre for Genomic and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine (S.E.H.), University of Edinburgh, Western General Hospital, Scotland, United Kingdom; Department of Epidemiology and Biostatistics, School of Public Health (W.Z., E.E., J.C.C., H.G., B.L., I.T., A.-C.V.), MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health (M.-R.J., P.E.), School of Public Health (N.P.), International Centre for Circulatory Health (S. Thom), and National Heart and Lung Institute (P.S.), Imperial College London, United Kingdom; Department of Cardiology, Ealing Hospital, London North West Healthcare NHS Trust, Southall, United Kingdom (W.Z., J.C.C., J.S.K.); Department of Medical Biology, Faculty of Medicine, University of Split, Croatia (T.Z.); Department of Hygiene and Epidemiology, University of Ioannina Medical School, Greece (E.E.); Medical Research Institute, University

of Dundee, Ninewells Hospital and Medical School, Scotland, United Kingdom (N. Shah, A.S.F.D., C.N.A.P.); Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan (N. Shah); National Institute for Health Research Biomedical Research Centre, London, United Kingdom (M.M.); Department of Human Genetics, Wellcome Trust Sanger Institute, United Kingdom (B.P.P., E.Z.); INSERM U 1219, Bordeaux Population Health Center, France (G.C., C.T., S.D.); Bordeaux University, France (G.C., C.T., S.D.); Hunter Medical Research Institute, New Lambton, NSW, Australia (C.O., E.G.H., R. Scott, J.A.); Center for Statistical Genetics, Department of Biostatistics, Ann Arbor, MI (G.A.); Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Iran (M.A.); Busselton Population Medical Research Institute, Western Australia (J.B., J.H.); PathWest Laboratory Medicine of Western Australia, Nedlands (J.B., J.H.); School of Pathology and Laboratory Medicine (J.B., J.H.), School of Population and Global Health (J.H.), and School of Medicine and Pharmacology (A. James), The University of Western Australia, Nedlands; Imperial College Healthcare NHS Trust, London, United Kingdom (J.C.C., J.S.K.); University of Dundee, Ninewells Hospital & Medical School, United Kingdom (J.C.); Institute of Genetic Medicine (H.J.C.), and Institute of Health and Society (C. Mamasoula), Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Pathology, Amsterdam Medical Center, The Netherlands (J.J.D.); Department of Numerical Analysis and Computer Science, Stockholm University, Sweden (M. Frånberg); Department of Public Health and Caring Sciences, Geriatrics, Uppsala, Sweden (V. Giedraitis); Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH), Neuherberg, Germany (C.G.); Department of Psychology, School of Social Sciences, Heriot-Watt University, Edinburgh, United Kingdom (A.J.G.); Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging (T.B.H., L.J.L.); Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A. Hofman); Center For Life-Course Health Research (M.-R.J.), and Biocenter Oulu (M.-R.J.), University of Oulu, Finland; Unit of Primary Care, Oulu University Hospital, Finland (M.-R.J.); National Heart, Lung and Blood Institute, Cardiovascular Epidemiology and Human Genomics Branch, Bethesda, MD (A.D.J.); Department of Clinical Physiology, Tampere University Hospital, Finland (M.K.); Department of Clinical Physiology, Faculty of Medicine and Life Sciences, University of Tampere, Finland (M.K.); Cardiovascular Research Center (S. Kathiresan, C.N.-C.); Center for Human Genetics (S. Kathiresan), and Center for Human Genetic Research (C.N.-C.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (S. Kathiresan, C.N.-C.); Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, United Kingdom (K.-T.K.); Department of Public Health, Faculty of Medicine, University of Split, Croatia (I.K., O.P.); Cardiology, Department of Specialties of Medicine, Geneva University Hospital, Switzerland (L. Lin, F.M., G.B.E.); Department of Medical Sciences, Cardiovascular Epidemiology (L. Lind, J.S.), and Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory (E.I.), Uppsala University, Sweden; Department of Psychiatry,

EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands (Y.M., B.W.J.H.P.); School of Molecular, Genetic and Population Health Sciences, University of Edinburgh, Medical School, Teviot Place, Scotland, United Kingdom (A.D.M.); Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston (A.C.M.); British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences (S.P.), and Institute of Cardiovascular and Medical Sciences, Faculty of Medicine (D.J.S.), University of Glasgow, United Kingdom; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland (A. Palotie, S.R., A.-P.S., M.P.); Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada (G.P., S. Thériault); Department of Neurology, General Central Hospital, Bolzano, Italy (P.P.P.); Department of Neurology, University of Lübeck, Germany (P.P.P.); Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Finland (O.T.R.); Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland (O.T.R.); Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China (M.R.); Harvard Medical School, Boston, MA (P.M.R., D.I.C.); Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (A.R.); Institute of Molecular Biology and Biochemistry, Centre for Molecular Medicine, Medical University of Graz, Austria (Y.S., H. Schmidt); INSERM U1078, Etablissement Français du Sang, Brest Cedex, France (A.S.P.); Faculty of Health, University of Newcastle, Callaghan, NSW, Australia (R. Scott, J.A.); John Hunter Hospital, New Lambton, NSW, Australia (R. Scott, J.A.); The New York Academy of Medicine, New York (D.S.); IRCCS Neuromed, Pozzilli, Isernia, Italy (R. Sorice, M. Ciullo); Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland (A.S.); Institute for Translational Genomics and Population Sciences, Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (K.D.T.); Division of Genetic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA (K.D.T.); Department of Public Health (C.T.), and Department of Neurology (S.D.), Bordeaux University Hospital, France; Department of Internal Medicine, Lausanne University Hospital, CHUV, Switzerland (P.V.); Population Health Research Institute, McMaster University, Hamilton Ontario, Canada (D.C.); National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, United Kingdom (J.S.K.); Dasman Diabetes Institute, Kuwait (J.T.); Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia (J.T.); Department of Neurosciences and Preventive Medicine, Danube-University Krems, Austria (J.T.); Division of Cardiovascular Sciences, The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, United Kingdom (B.D.K.); Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem (Y.M.L.); Kaiser Permanent Washington Health Research Institute, Seattle, WA (B.M.P.); Institute of Physiology, University Medicine Greifswald, Karlsburg, Germany (R.R); Department of Pulmonary Physiology and Sleep, Sir Charles Gairdner Hospital, Nedlands,

Western Australia (A. James); Population Health Research Institute, St George's, University of London, United Kingdom (D.P.S.); Department of Medicine, Columbia University Medical Center, New York (W.P.); Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, CA (E.I.); Data Science Institute and Lancaster Medical School, Lancaster University, United Kingdom (J.K.); and Department of Biostatistics, University of Liverpool, United Kingdom (A.P.M.).

Acknowledgments

References

1. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P. The support of human genetic evidence for approved drug indications. Nat Genet. 2015; 47: 856–860. DOI: 10.1038/ng.3314 [PubMed: 26121088]

2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159–2219. DOI: 10.1093/eurheartj/eht151 [PubMed: 23771844]

3. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478: 103–109. [PubMed: 21909115]

4. Ganesh SK, Chasman DI, Larson MG, et al. Global Blood Pressure Genetics Consortium. Effects of long-term averaging of quantitative blood pressure traits on the detection of genetic associations. Am J Hum Genet. 2014; 95: 49–65. DOI: 10.1016/j.ajhg.2014.06.002 [PubMed: 24975945]

5. Johnson AD, Newton-Cheh C, Chasman DI, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; Global BPgen Consortium; Women's Genome Health Study. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension. 2011; 57: 903–910. DOI: 10.1161/HYPERTENSIONAHA.110.158667 [PubMed: 21444836]

6. Johnson T, Gaunt TR, Newhouse SJ, et al. Cardiogenics Consortium; Global BPgen Consortium. Blood pressure loci identified with a gene-centric array. Am J Hum Genet. 2011; 89: 688–700. DOI: 10.1016/j.ajhg.2011.10.013 [PubMed: 22100073]

7. Kato N, Takeuchi F, Tabara Y, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011; 43: 531–538. DOI: 10.1038/ng.834 [PubMed: 21572416]

8. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009; 41: 677–687. DOI: 10.1038/ng.384 [PubMed: 19430479]

9. Newton-Cheh C, Johnson T, Gateva V, et al. Wellcome Trust Case Control Consortium. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009; 41: 666–676. DOI: 10.1038/ng.361 [PubMed: 19430483]

10. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009; 41: 348–353. DOI: 10.1038/ng.328 [PubMed: 19219041]

11. Padmanabhan S, Melander O, Johnson T, et al. Global BPgen Consortium. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 2010; 6: e1001177. doi: 10.1371/journal.pgen.1001177 [PubMed: 21082022]

12. Simino J, Shi G, Bis JC, et al. LifeLines Cohort Study. Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. Am J Hum Genet. 2014; 95: 24–38. DOI: 10.1016/j.ajhg.2014.05.010 [PubMed: 24954895]

13. Tragante V, Barnes MR, Ganesh SK, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. Am J Hum Genet. 2014; 94: 349–360. DOI: 10.1016/j.ajhg.2013.12.016 [PubMed: 24560520]

14. Wain LV, Verwoert GC, O'Reilly PF, et al. LifeLines Cohort Study; EchoGen consortium; AortaGen Consortium; CHARGE Consortium Heart Failure Working Group; KidneyGen consortium; CKDGen consortium; Cardiogenics consortium; CardioGram. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011; 43: 1005–1011. DOI: 10.1038/ng.922 [PubMed: 21909110]

15. Ehret GB, Ferreira T, Chasman DI, et al. CHARGE-EchoGen Consortium; CHARGE-HF Consortium; Wellcome Trust Case Control Consortium. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet. 2016; 48: 1171–1184. DOI: 10.1038/ng.3667 [PubMed: 27618452]

16. Liu C, Kraja AT, Smith JA, et al. CHD Exome+ Consortium; ExomeBP Consortium; GoT2DGenes Consortium; T2D-GENES Consortium; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia; CKDGen Consortium. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat Genet. 2016; 48: 1162–1170. DOI: 10.1038/ng.3660 [PubMed: 27618448]

17. Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok PY, Iribarren C, Chakravarti A, Risch N. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. Nat Genet. 2017; 49: 54–64. DOI: 10.1038/ng.3715 [PubMed: 27841878]

18. Surendran P, Drenos F, Young R, et al. CHARGE-Heart Failure Consortium; EchoGen Consortium; METASTROKE Consortium; GIANT Consortium; EPIC-InterAct Consortium; Lifelines Cohort Study; Wellcome Trust Case Control Consortium; Understanding Society Scientific Group; EPIC-CVD Consortium; CHARGE+ Exome Chip Blood Pressure Consortium; T2DGENES Consortium; GoT2DGenes Consortium; ExomeBP Consortium; CHD Exome+

Consortium. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet. 2016; 48: 1151–1161. DOI: 10.1038/ng.3654 [PubMed: 27618447]

19. Warren HR, Evangelou E, Cabrera CP, et al. International Consortium of Blood Pressure (ICBP) 1000G Analyses; BIOS Consortium; Lifelines Cohort Study; Understanding Society Scientific group; CHD Exome+ Consortium; ExomeBP Consortium; T2D-GENES Consortium; GoT2DGenes Consortium; Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium; International Genomics of Blood Pressure (iGEN-BP) Consortium; UK Biobank CardioMetabolic Consortium BP working group. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017; 49: 403–415. DOI: 10.1038/ng.3768 [PubMed: 28135244]

20. Safar ME, Nilsson PM, Blacher J, Mimran A. Pulse pressure, arterial stiffness, and end-organ damage. Curr Hypertens Rep. 2012; 14: 339–344. DOI: 10.1007/s11906-012-0272-9 [PubMed: 22555981]

21. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med. 2005; 24: 2911–2935. DOI: 10.1002/sim.2165 [PubMed: 16152135]

22. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491: 56–65. DOI: 10.1038/nature11632 [PubMed: 23128226]

23. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011; 88: 76–82. DOI: 10.1016/j.ajhg.2010.11.011 [PubMed: 21167468]

24. Kato N, Loh M, Takeuchi F, et al. BIOS-consortium; CARDIo GRAMplusCD; LifeLines Cohort Study; InterAct Consortium. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet. 2015; 47: 1282–1293. DOI: 10.1038/ng.3405 [PubMed: 26390057]

25. GTEx Consortium. Human genomics. The genotype-tissue expression (gtex) pilot analysis: Multitissue gene regulation in humans. Science. 2015; 348: 648–660. DOI: 10.1126/science.1262110 [PubMed: 25954001]

26. Damman J, Bloks VW, Daha MR, van der Most PJ, Sanjabi B, van der Vlies P, Snieder H, Ploeg RJ, Krikke C, Leuvenink HG, Seelen MA. Hypoxia and complement-and-coagulation pathways in the deceased organ donor as the major target for intervention to improve renal allograft outcome. Transplantation. 2015; 99: 1293–1300. DOI: 10.1097/TP.0000000000000500 [PubMed: 25427168]

27. Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files. Bioinformatics. 2011; 27: 718–719. DOI: 10.1093/bioinformatics/btq671 [PubMed: 21208982]

28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81: 559–575. DOI: 10.1086/519795 [PubMed: 17701901]

29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38: e164. doi: 10.1093/nar/gkq603 [PubMed: 20601685]

30. Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res. 2013; 41 (database issue) D793–D800. DOI: 10.1093/nar/gks1055 [PubMed: 23143270]

31. Vaez A, Jansen R, Prins BP, Hottenga JJ, de Geus EJ, Boomsma DI, Penninx BW, Nolte IM, Snieder H, Alizadeh BZ. In silico post genome-wide association studies analysis of C-reactive protein loci suggests an important role for interferons. Circ Cardiovasc Genet. 2015; 8: 487–497. DOI: 10.1161/CIRCGENETICS.114.000714 [PubMed: 25752597]

32. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD, Ideker T. A travel guide to Cytoscape plugins. Nat Methods. 2012; 9: 1069–1076. DOI: 10.1038/nmeth.2212 [PubMed: 23132118]

33. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 2008; 9 (suppl 1) S4. doi: 10.1186/gb-2008-9-s1-s4

34. Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, Morris Q, Bader GD. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010; 26: 2927–2928. DOI: 10.1093/bioinformatics/btq562 [PubMed: 20926419]

35. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25: 25–29. DOI: 10.1038/75556 [PubMed: 10802651]

36. Dunham I, Kulesha E, Iotchkova V, Morganella S, Birney E. Forge: A tool to discover cell specific enrichments of gwas associated snps in regulatory regions. BioRxiv. 2014; doi: 10.1101/013045

37. Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, Walker JR, Wilson RK, Mardis ER, Griffith M, Griffith OL. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016; 44 (D1) D1036–D1044. DOI: 10.1093/nar/gkv1165 [PubMed: 26531824]

38. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Optimal designs for two-stage genome-wide association studies. Genet Epidemiol. 2007; 31: 776–788. DOI: 10.1002/gepi.20240 [PubMed: 17549752]

39. Trevisan M, Ostrow D, Cooper R, Liu K, Sparks S, Okonek A, Stevens E, Marquardt J, Stamler J. Abnormal red blood cell ion transport and hypertension. The People's Gas Company study. Hypertension. 1983; 5: 363–367. [PubMed: 6840823]

40. Wright FA, Sullivan PF, Brooks AI, et al. Heritability and genomics of gene expression in peripheral blood. Nat Genet. 2014; 46: 430–437. DOI: 10.1038/ng.2951 [PubMed: 24728292]

41. Jansen R, Batista S, Brooks AI, et al. Sex differences in the human peripheral blood transcriptome. BMC Genomics. 2014; 15: 33. doi: 10.1186/1471-2164-15-33 [PubMed: 24438232]

42. Zhernakova DV, Deelen P, Vermaat M, et al. Identification of context-dependent expression quantitative trait loci in whole blood. Nat Genet. 2017; 49: 139–145. DOI: 10.1038/ng.3737 [PubMed: 27918533]

43. Marusugi K, Nakano K, Sasaki H, Kimura J, Yanobu-Takanashi R, Okamura T, Sasaki N. Functional validation of tensin2 SH2-PTB domain by CRISPR/Cas9-mediated genome editing. J Vet Med Sci. 2016; 78: 1413–1420. DOI: 10.1292/jvms.16-0205 [PubMed: 27246398]

44. Jeggle P, Smith ES, Stewart AP, Haerteis S, Korbmacher C, Edwardson JM. Atomic force microscopy imaging reveals the formation of ASIC/ENaC cross-clade ion channels. Biochem Biophys Res Commun. 2015; 464: 38–44. DOI: 10.1016/j.bbrc.2015.05.091 [PubMed: 26032502]

45. Carrier L, Mearini G, Stathopoulou K, Cuello F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. 2015; 573: 188–197. DOI: 10.1016/j.gene.2015.09.008 [PubMed: 26358504]

Novelty and Significance

What Is New?

- The root origin of hypertension and, hence, blood pressure (BP) variability in the population remains unclear.

- This study adds data to explain the genetic basis of BP variability and identifies genes likely active in BP-regulating pathways.

What Is Relevant?

- The results are of relevance for scientists, clinicians, and pharmacologists interested in hypertension.

- The BP loci and the BP genes identified constitute new leads for the understanding of BP pathogenesis and possibly therapeutic innovation.

Summary

Using 1000 Genomes Project–based imputation in 150 134 European ancestry and independent replication in a further 228 245 individuals, we contribute 8 replicated BP loci to the collection of loci currently known. Using these and previous data, 48 BP genes are identified for priority follow-up.

Figure.
Overlap of expression quantitative trait loci (eQTL) evidence from 4 whole-blood and 1 kidney resource. The figure indicates overlap of evidence for eQTLs from 4 whole-blood studies (SABRe, NESDA-NTR, BIOS, and GTEx) and from 1 kidney resource (TransplantLines). Every colored line indicates that this gene was analysis-wide significant in a given resource. Only genes identified by at least 2 resources are shown. The genes are sorted by genomic position on the *y* axis.

Table 1

Novel Genome-Wide Significant Signals of Association

Variant ID (Noncoded/Coded Allele), Chr:Position, Nearest Gene(s) (Type*)	CAF	Results for Most Significant Trait									Stage 1+Stage 2 Meta-Analysis P Values for All Traits			
		Stage 1		Stage 2			Stage 1+Stage 2			Neff	SBP	DBP	PP	
		Beta (SE)	P Value	Neff	Beta (SE)	P Value	Neff	Beta (SE)	P Value					
SBP														
rs1048238 (C/T), 1:16341649, *HSPB7* (3'UTR)	0.571	0.366 (0.074)	8.09E-07	140299	NA	NA	NA	NA	NA	NA	NA	NA	NA	
rs848309 (proxy) (T/C), 1:16308447	0.567	0.347 (0.072)	1.70E-06	146755	0.347 (0.071)	9.10E-07	140462	0.347 (0.051)	7.07E-12‡	287217	7.07E-12‡	1.07E-10‡	5.48E-06	
rs185819 (T/C),† 6:32,050,067, *TNXB* (ns)	0.513	0.534 (0.073)	1.93E-13‡	142397	0.277 (0.053)	1.49E-07	221748	0.365 (0.043)	1.04E-17‡	364144	1.04E-17‡	2.24E-11‡	8.50E-15‡	
rs6557876 (C/T), 8:25,900,675, *EBF2*	0.252	−0.411 (0.084)	8.50E-07	143653	−0.350 (0.060)	5.66E-09‡	225803	−0.371 (0.049)	2.85E-14‡	369457	2.85E-14‡	2.50E-10‡	1.51E-08‡	
rs35783704 (G/A), 8:105,966,258, *LRP12/ZFPM2*	0.109	−0.609 (0.121)	4.96E-07	133924	−0.310 (0.089)	4.78E-04	215528	−0.414 (0.072)	7.08E-09‡	349452	7.08E-09‡	1.60E-06	2.92E-07	
rs73099903 (C/T), 12:53,440,779, *LOC283335*	0.074	0.768 (0.143)	8.05E-08	136064	0.396 (0.098)	5.32E-05	207253	0.515 (0.081)	1.95E-10‡	343318	1.95E-10‡	4.53E-06	5.46E-08	
rs8904 (G/A), 14:35,871,217, *NFKBIA* (3'UTR)	0.375	0.377 (0.076)	6.76E-07	140424	0.278 (0.054)	2.31E-07	224771	0.311 (0.044)	1.31E-12‡	365195	1.31E-12‡	1.13E-04	3.44E-12‡	
rs57927100 (C/G), 17:75,317,300, *SEPT9*	0.258	−0.489 (0.086)	1.10E-08‡	136624	−0.220 (0.061)	3.12E-04	210563	−0.310 (0.050)	4.04E-10‡	347188	4.04E-10‡	1.16E-10‡	1.81E-05	
DBP														
rs9710247 (A/G), 19:40,760,449, *AKT2*	0.447	0.252 (0.051)	8.11E-07	109695	0.129 (0.032)	5.76E-05	198332	0.164 (0.027)	1.61E-09‡	308028	3.82E-02	1.61E-09‡	5.03E-01	

Results from stage 1 and stage 2, and the meta-analysis of stage 1 and stage 2, for all novel genome-wide significant signals of association. P values of association for all 3 traits from a meta-analysis of stages 1 and 2 are also presented. Results from proxy SNPs are indicated by (proxy): rs848309 was a proxy SNP for rs1048238, and rs10926988 was a proxy SNP for chr1:243458005:INDEL. CAF indicates coded allele frequency; Neff, effective sample size; ns, nonsynonymous; PP, pulse pressure; s, synonymous; SBP, systolic blood pressure; and UTR, untranslated region.

*
For intragenic variants, the nearest genes are listed; all other variants are intronic unless indicated otherwise.

†
Novel signal at previously reported locus.

‡
Genome-wide significant P values (P<5×10⁻⁸).

Table 2

BP-Associated SNPs Associated With Expression of the Same Gene Across 4 or 3 Independent Whole-Blood eQTL Resources and the Kidney Resource

Sentinel SNP	Chr	Position	Gene	Blood Data Sets	Top eQTL	Signal in Other Tissue(s) in GTEx	Signal in Kidney	eQTL Signal Previously Reported
Signal in 4 whole-blood eQTL resources								
rs17367504	1	11862778	CLCN6	YYYY		Y		Y
rs2169137	1	204497913	MDM4	YYYY	Y	Y		Y
rs10926988	1	243483279	SDCCAG8	YYYY		Y		
rs319690	3	47927484	MAP4	YYYY	Y	Y		Y
rs12521868	5	131784393	SLC22A5	YYYY		Y		
rs900145	11	13293905	ARNTL	YYYY		Y		Y
rs1060105	12	123806219	CDK2AP1	YYYY	Y	Y	Y	
rs1378942	15	75077367	SCAMP2	YYYY				
rs1126464	16	89704365	CHMP1A	YYYY		Y		Y
rs1126464	16	89704365	FANCA	YYYY				Y
rs12946454	17	43208121	DCAKD	YYYY		Y	Y	Y
Signal in 3 (out of 4) whole-blood eQTL resources								
rs17367504	1	11862778	MTHFR	YYYN		Y		Y
rs871524	1	38411445	FHL3	NYYY		Y		
rs871524	1	38411445	SF3A3	NYYY		Y		
rs4660293	1	40028180	PABPC4	YYYN	Y	Y		Y
rs6749447	2	169041386	STK39	YYYN	Y			
rs347591	3	11290122	ATG7	YYYN		Y		
rs319690	3	47927484	ZNF589	YYNY		Y		
rs12521868	5	131784393	SLC22A4	YYYN		Y		
rs1563788	6	43308363	CRIP3	YYYN	Y			Y
rs10943605	6	79655477	PHIP	YYYN	Y	Y		Y
rs4728142	7	128573967	IRF5	NYYY		Y	Y	Y
rs4728142	7	128573967	TNPO3	YYYN			Y	
rs2898290	8	11433909	BLK	YYYN		Y		

Sentinel SNP	Chr	Position	Gene	Blood Data Sets	Top eQTL	Signal in Other Tissue(s) in GTEx	Signal in Kidney	eQTL Signal Previously Reported
rs2898290	8	11433909	FAM167A	NYYY		Y		
rs2898290	8	11433909	FDFT1	YYYY		Y		
rs2071518	8	120435812	NOV	YYYY		Y		
rs76452347	9	35906471	TPM2	YYYY				
rs10760117	9	123586737	MEGF9	YYYY		Y		Y
rs4494250	10	96563757	HELLS	YYYY				Y
rs11191548	10	104846178	NT5C2	YYYY	Y			
rs661348	11	1905292	TNNT3	NYYY		Y		
rs2649044	11	9763969	SBF2	YYYY				
rs2649044	11	9763969	SWAP70	YYYY	Y	Y		?
rs7129220	11	10350538	ADM	YYYY				Y
rs7103648	11	47461783	MYBPC3	YYYY				
rs3741378	11	65408937	CTSW	YYYY				
rs7302981	12	50537815	LIMA1	YYYY				Y
rs7302981	12	50537815	ATF1	YYNY		Y		
rs1036477	15	48914926	FBN1	YNYY				
rs1378942	15	75077367	CSK	YYYY	Y	Y		Y
rs1378942	15	75077367	MPI	NYYY		Y		
rs1378942	15	75077367	ULK3	YNYY		Y		Y
rs12946454	17	43208121	NMT1	YYYY				Y
rs2304130	19	19789528	GATAD2A	YYYY				
rs867186	20	33764554	EIF6	NYYY		Y		
rs6095241	20	47308798	PREX1	YYYY				
rs9306160	21	45107562	RRP1B	YNYY	Y	Y		Y

Signals of association of SNP genotype and gene expression in other nonblood tissues in GTEx and in kidney are also indicated. Blood data set order: (1) SABRe, (2) NESDA-NTR, (3) BIOS, and (4) GTEx (whole-blood). Top eQTL: top GWAS SNP is top eQTL SNP (or in high LD, $r^2 > 0.9$, with top eQTL SNP) in at least 1 data set. eQTL signal previously reported: Genes for which eQTL signals have been previously reported for that sentinel SNP.[15,16,18] For full list, see Table S12 in the online-only Data Supplement. eQTL indicates expression quantitative trait loci; GWAS, genome-wide association studies; GTEx, genotype-tissue expression; and LD, linkage disequilibrium; and SABRe, Systems Approach to Biomarker Research in Cardiovascular Disease.